Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label R-MPT salvage therapy study in relapsed/refractory multiple myeloma
2006-007087-28Phase 2Active
- Sponsor
- Fondazione EMN Italy
- Start
- Mar 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, melphalan, prednisone and thalidomide in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoints: Safety profile of R-MPT salvage treatment, Partial response rate and 1 more. Started Mar 2007; status: active.
02
Drugs
lenalidomidemelphalanprednisonethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-007087-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007087-28.